Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12159703 | 0.89 | CA1 (0.53) | CA1CA2SMN1; SMN2KMT2ACA14 | |
| SCHEMBL812437 | 0.89 | CA1 (0.39) | CA1CA2SMN1; SMN2KMT2AMME | |
| SCHEMBL9715137 | 0.85 | MET (0.38) | CA1CA2SMN1; SMN2KMT2AMME | |
| SCHEMBL489820 | 0.85 | MME (0.45) | CA1CA2SMN1; SMN2MME | |
| SCHEMBL490028 | 0.85 | CA1 (0.41) | CA1CA2SMN1; SMN2KMT2AMET | |
| SCHEMBL490230 | 0.85 | MME (0.45) | CA1CA2SMN1; SMN2MME | |
| SCHEMBL489822 | 0.85 | MME (0.45) | CA1CA2SMN1; SMN2MME | |
| SCHEMBL490027 | 0.85 | CA1 (0.41) | CA1CA2SMN1; SMN2KMT2AMET | |
| SCHEMBL490175 | 0.85 | CA1 (0.41) | CA1CA2SMN1; SMN2KMT2AMET | |
| SCHEMBL23486881 | 0.82 | CA1 (0.39) | CA1CA2SMN1; SMN2KMT2AZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4355729-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Celgene Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117500785-A | Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2022266162-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266162-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007081889-A2 | PRODUCTION OF DOLASETRON | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007072506-A2 | POLYMORPHIC FORMS OF DOLASETRON MESYLATE AND PROCESSES THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072507-A2 | POLYMORPHIC FORMS OF DOLASETRON BASE AND PROCESSES OF PREPARING DOLASETRON BASE, ITS POLYMORPHIC FORMS AND SALT THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
| US-20060235044-A1 | Azabicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-19 | — | — | US | disclosed |
| EP-1622907-A1 | AZABICYCLONONENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096803-A1 | AZABICYCLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, LPAR5, S1PR2 | CA1 1240/4885CA2 1661/4885SMN1; SMN2 15/4885 |
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, LPAR5, S1PR2 | CA1 1240/4885CA2 1661/4885SMN1; SMN2 15/4885 |
| US-20060235044-A1 | Azabicyclononene derivatives | REN, ACE, ACE2 | CA1 3526/4885CA2 1246/4885SMN1; SMN2 4720/4885 |
| US-20070203175-A1 | Productioin of dolasetron | DDOST, ALG8, DUT | CA1 4197/4885CA2 3951/4885SMN1; SMN2 2361/4885 |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | CA1 1240/4885CA2 1661/4885SMN1; SMN2 15/4885 |
| US-20070203219-A1 | Production of dolasetron | DDOST, DAD1, DHPS | CA1 2636/4885CA2 1125/4885SMN1; SMN2 3702/4885 |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, CLN6, SNCA | CA1 916/4885CA2 325/4885SMN1; SMN2 12/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CA1 2461/4885CA2 2993/4885SMN1; SMN2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.